{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:06:05Z","timestamp":1793563565968,"version":"4.5.0"},"reference-count":51,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T00:00:00Z","timestamp":1242000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Amyotrophic lateral sclerosis (ALS) is a devastating, and currently incurable, neuromuscular disease in which oxidative stress and mitochondrial impairment are contributing to neuronal loss. Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial cofactor, has shown promise in ALS transgenic mice, and in clinical trials for neurodegenerative diseases other than ALS. Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We designed and implemented a multicenter trial with an adaptive, two\u2010stage, bias\u2010adjusted, randomized, placebo\u2010controlled, double\u2010blind, Phase II design (n = 185). The primary outcome in both stages was a decline in the ALS Functional Rating Scale\u2010revised (ALSFRSr) score over 9 months. Stage 1 (dose selection, 35 participants per group) compared CoQ10 doses of 1,800 and 2,700mg\/day. Stage 2 (futility test, 75 patients per group) compared the dose selected in Stage 1 against placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Stage 1 selected the 2,700mg dose. In Stage 2, the pre\u2010specified primary null hypothesis that this dose is superior to placebo was not rejected. It was rejected, however, in an accompanying prespecified sensitivity test, and further supplementary analyses. Prespecified secondary analyses showed no significant differences between CoQ10 at 2,700mg\/day and placebo. There were no safety concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>CoQ10 at 2,700mg daily for 9 months shows insufficient promise to warrant Phase III testing. Given this outcome, the adaptive Phase II design incorporating a dose selection and a futility test avoided the need for a much larger conventional Phase III trial. Ann Neurol 2009;66:235\u2013244<\/jats:p><\/jats:sec>","DOI":"10.1002\/ana.21743","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T14:25:25Z","timestamp":1242051925000},"page":"235-244","source":"Crossref","is-referenced-by-count":210,"title":["Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III"],"prefix":"10.1002","volume":"66","author":[{"given":"Petra","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.P.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Shefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S.","family":"Krivickas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlayne E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Tiryaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lomen\u2010Hoerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Armon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rup","family":"Tandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy A.","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Rezania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sufit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pestronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Novella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Heiman\u2010Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Kasarskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"Pioro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Arbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darleen","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Barsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mitsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530180041015"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.504"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.2.280"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(93)90245-T"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-1026-z"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000296811.19811.db"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/362059a0"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2004.12.021"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.09.038"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10715760701877262"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/17482960801933942"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.10.1758"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2004.09.030"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/146608202760196048"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01112.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-3042.2001.00731.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2007.03.009"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2001.10719063"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10715760290021315"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.14.1.87"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.15.8892"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420221"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520250113"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520180218"},{"key":"e_1_2_7_26_2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","article-title":"Tolerance of high\u2010dose (3,000 mg\/day) coenzyme Q10 in ALS","volume":"65","author":"Ferrante KL","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmr.2008.03.001"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.05.003"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/17434470410019735"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/146608200300079536"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/130.9.2343"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20316"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0220-1"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)00237-2"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00210-5"},{"key":"e_1_2_7_36_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1212\/01.wnl.0000201182.60750.66","article-title":"A two\u2010stage design for a phase II clinical trial of coenzyme Q10 in ALS","volume":"66","author":"Levy G","year":"2006","journal-title":"Neurology"},{"key":"e_1_2_7_37_2","volume-title":"Selecting and ordering populations: a new statistical methodology","author":"Gibbons JD","year":"1977"},{"key":"e_1_2_7_38_2","volume-title":"Design and analysis of experiments for statistical selection, screening, and multiple comparisons","author":"Bechofer RE","year":"1995"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000185722.99167.56"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000185718.26377.07"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20361"},{"key":"e_1_2_7_42_2","first-page":"725","article-title":"Changes in the normal maximal expiratory flow\u2010volume curve with growth and aging","volume":"127","author":"Knudson RJ","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00113-6"},{"key":"e_1_2_7_46_2","unstructured":"National Cancer Institute's. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available at:http:\/\/ctep.info.nih.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed June 29 2009."},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/17434470410019753"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.4.456"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/17482960600888156"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148648.38313.64"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91680-3"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200809040-00003"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.21743","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.21743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:40:14Z","timestamp":1697449214000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.21743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/ana.21743"],"URL":"https:\/\/doi.org\/10.1002\/ana.21743","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}